SCOTTSDALE, Ariz.--(BUSINESS WIRE)--ImmuneRegen BioSciences, Inc. (OTCBB:IRBO) and DelSite Biotechnologies, Inc., a wholly owned subsidiary of Carrington Laboratories, Inc. (OTCBB:CARN.OB), today announced an agreement to work together to design and develop novel new treatments to prevent the spread of pandemic flu.
